Cell Genesys, Inc. (CEGE)

[dav1234]

Law Office of Brodsky & Smith, LLC Announces Investigation on Behalf of Shareholders of Cell Genesys, Inc.

More News related to BPAX

* Law Office of Brodsky & Smith, LLC Announces Investigation on Behalf of Shareholders of Cell Genesys, Inc.
* Levi & Korsinsky LLP Investigates Board of Cell Genesys, Inc.
* Notable Mergers and Acquisitions of the Day 6/30: BRCM/ELX, BPAX/CEGE, PTRY
* BioSante (BPAX) and Cell Genesys (CEGE) Agree to Merge; Deal Valued at $38M
* BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement

More News related to BPAX
More News related to CEGE

* Law Office of Brodsky & Smith, LLC Announces Investigation on Behalf of Shareholders of Cell Genesys, Inc.
* Levi & Korsinsky LLP Investigates Board of Cell Genesys, Inc.
* Notable Mergers and Acquisitions of the Day 6/30: BRCM/ELX, BPAX/CEGE, PTRY
* BioSante (BPAX) and Cell Genesys (CEGE) Agree to Merge; Deal Valued at $38M
* BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement

More News related to CEGE
More News related to Press Releases

* USA Technologies, Inc. Announces Record Date for Rights Offering
* CorpBanca Files Form 20-F
* Eurotin Inc.: Press Release
* Investors Real Estate Trust Reports Fourth Quarter 2009 Financial and Operating Results
* Eurotin Inc.: Press Release

More News related to Press Releases
June 30, 2009 2:47 PM EDT

BALA CYNWYD, Pa., June 30, 2009 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cell Genesys, Inc. ("Cell Genesys" or the "Company") (Nasdaq: CEGE) related to the proposed merger with BioSante Pharmaceuticals, Inc. ("BioSante") (Nasdaq: BPAX) in an all stock deal. BioSante has offered Cell Genesys shareholders $0.1615 a share for their stock. Based on BioSante's closing price on June 29, 2009, the deal is presently worth $0.347 a share for Cell Genesys shareholders, with the total consideration being approximately $38 million. The deal appears to be unfair, in part, given the fact that since April 2009, Cell Genesys stock has traded at or above the offer price and as recently as May 2008 traded at over $0.68 a share. Moreover, the 200 day Moving Average on BioSante shares is only $1.75.

If you are a Cell Genesys shareholder and wish to discuss the legal ramifications of the proposed acquisition by BioSante, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at [e-mail], or by calling toll free 877-LEGAL-90.

http://www.streetinsider.com/Press+Releases/Law+Office+of+Brodsky+&%3B+Smith,+LLC+Announces+Investigation+on+Behalf+of+Shareholders+of+Cell+Genesys,+Inc./4764268.html